Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Everolimus - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for everolimus?

Everolimus is the generic ingredient in three branded drugs marketed by Novartis and Novartis Pharm, and is included in three NDAs. There are eleven patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and two patent family members in thirty-nine countries.

There are ten drug master file entries for everolimus. One supplier is listed for this compound.

Summary for Generic Name: everolimus

Tradenames:3
Patents:12
Applicants:2
NDAs:3
Drug Master File Entries: see list10
Suppliers / Packagers: see list1
Bulk Api Vendors: see list16
Clinical Trials: see list385
Patent Applications: see list7,242
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:everolimus at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-003Apr 20, 2010RXYesYes6,004,973*PED► SubscribeY► Subscribe
Novartis
AFINITOR
everolimus
TABLET;ORAL022334-001Mar 30, 2009RXYesNo► Subscribe► Subscribe
Novartis
AFINITOR
everolimus
TABLET;ORAL022334-004Mar 30, 2012RXYesNo8,436,010*PED► SubscribeY► Subscribe
Novartis
AFINITOR
everolimus
TABLET;ORAL022334-001Mar 30, 2009RXYesNo7,297,703*PED► SubscribeY► Subscribe
Novartis
AFINITOR
everolimus
TABLET;ORAL022334-003Jul 9, 2010RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: everolimus

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharm
AFINITOR DISPERZ
everolimus
TABLET, FOR SUSPENSION;ORAL203985-001Aug 29, 20126,004,973*PED► Subscribe
Novartis Pharm
AFINITOR DISPERZ
everolimus
TABLET, FOR SUSPENSION;ORAL203985-003Aug 29, 20126,004,973*PED► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-003Apr 20, 20106,004,973*PED► Subscribe
Novartis Pharm
AFINITOR DISPERZ
everolimus
TABLET, FOR SUSPENSION;ORAL203985-002Aug 29, 20126,004,973*PED► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-003Apr 20, 20106,440,990*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: everolimus

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,572,804Macrolides► Subscribe
6,852,729 Macrolides► Subscribe
6,605,613 Macrolides► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: everolimus

Country Document Number Estimated Expiration
Brazil9915986► Subscribe
Czech Republic302210► Subscribe
United Kingdom0602747► Subscribe
World Intellectual Property Organization (WIPO)2007057457► Subscribe
Australia2010202866► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc